Prospective Study of Antidepressant Treatment of Psychiatric Patients with Depressive Disorders: Treatment Adequacy and Outcomes

Overview

Journal BMC Psychiatry

Publisher Biomed Central

Specialty Psychiatry

Date 2023 Nov 29

PMID 38017416

Authors

Johanna von Knorring

Ilya Baryshnikov

Pekka Jylha

Tiina Talaslahti

Martti Heikkinen

Erkki Isometsa

Affiliations

Soon will be listed here.

Abstract

Background: Despite numerous national depression care guidelines (DCGs), suboptimal antidepressant treatment may occur. We examined DCG concordance and depression treatment outcomes in psychiatric settings.

Methods: We evaluated treatment received and outcomes of 128 psychiatric out- and inpatients participating in the PEGAD (Pharmacoepidemiology and Pharmacogenetics of Antidepressant Treatment for Depressive Disorders) study at baseline, two weeks, and eight weeks using interviews and questionnaires. Inclusion criteria were ICD-10 diagnosis of a depressive disorder, a Patient Health Questionnaire-9 symptom (PHQ-9) score ≥ 10, and a new antidepressant prescribed. The primary outcome of the study was within-individual change in PHQ-9 scores.

Results: At baseline, patients had predominately recurrent (83%) and in 19% treatment-resistant depression (TRD). The median preceding duration of the current episode was 6.5 months. At eight weeks, 85% of the patients (n = 107) used a DCG-concordant antidepressant dose. However, due to the scarcity of antidepressant combinations and augmentations, fewer TRD than non-TRD patients (25% vs. 84%, p < 0.005) received adequate antidepressant treatment. Additionally, one-third of the patients received inadequate follow-up. Overall, only 53% received treatment compatible with DCG recommendations for adequate pharmacotherapy and follow-up. The mean decline in PHQ-9 scores (-3.8 ± SD 5.7) was significant (p < 0.0005). Nearly 40% of the patients reached a subthreshold level of depression (PHQ-9 < 10), predicted by a lower baseline PHQ-9 score, recurrent depression, and female sex. However, 45% experienced no significant clinical improvement (PHQ-9 score reduction < 20%).

Conclusions: Our findings suggest that inadequate treatment continues to occur in psychiatric care settings, particularly for TRD patients.

References

Gabilondo A, Rojas-Farreras S, Rodriguez A, Fernandez A, Pinto-Meza A, Vilagut G . Use of primary and specialized mental health care for a major depressive episode in Spain by ESEMeD respondents. Psychiatr Serv. 2011; 62(2):152-61. DOI: 10.1176/ps.62.2.pss6202_0152. View

Henssler J, Alexander D, Schwarzer G, Bschor T, Baethge C . Combining Antidepressants vs Antidepressant Monotherapy for Treatment of Patients With Acute Depression: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2022; 79(4):300-312. PMC: 8851370. DOI: 10.1001/jamapsychiatry.2021.4313. View

Mahlich J, Tsukazawa S, Wiegand F . Estimating Prevalence and Healthcare Utilization for Treatment-Resistant Depression in Japan: A Retrospective Claims Database Study. Drugs Real World Outcomes. 2017; 5(1):35-43. PMC: 5825389. DOI: 10.1007/s40801-017-0126-5. View

Hirschfeld R . The Mood Disorder Questionnaire: A Simple, Patient-Rated Screening Instrument for Bipolar Disorder. Prim Care Companion J Clin Psychiatry. 2004; 4(1):9-11. PMC: 314375. DOI: 10.4088/pcc.v04n0104. View

Cipriani A, Furukawa T, Salanti G, Chaimani A, Atkinson L, Ogawa Y . Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018; 391(10128):1357-1366. PMC: 5889788. DOI: 10.1016/S0140-6736(17)32802-7. View

Gaynes B, Rush A, Trivedi M, Wisniewski S, Spencer D, Fava M . The STAR*D study: treating depression in the real world. Cleve Clin J Med. 2008; 75(1):57-66. DOI: 10.3949/ccjm.75.1.57. View

Trivedi M . Tools and strategies for ongoing assessment of depression: a measurement-based approach to remission. J Clin Psychiatry. 2009; 70 Suppl 6:26-31. DOI: 10.4088/JCP.8133su1c.04. View

Kroenke K, Spitzer R, Williams J . The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001; 16(9):606-13. PMC: 1495268. DOI: 10.1046/j.1525-1497.2001.016009606.x. View

Taylor R, Marwood L, Oprea E, DeAngel V, Mather S, Valentini B . Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines. Int J Neuropsychopharmacol. 2020; 23(9):587-625. PMC: 7710919. DOI: 10.1093/ijnp/pyaa033. View

10.

Xiao L, Qi H, Zheng W, Xiang Y, Carmody T, Mayes T . The effectiveness of enhanced evidence-based care for depressive disorders: a meta-analysis of randomized controlled trials. Transl Psychiatry. 2021; 11(1):531. PMC: 8520525. DOI: 10.1038/s41398-021-01638-7. View

11.

Satyanarayana S, Enns M, Cox B, Sareen J . Prevalence and correlates of chronic depression in the canadian community health survey: mental health and well-being. Can J Psychiatry. 2009; 54(6):389-98. DOI: 10.1177/070674370905400606. View

12.

Rush A, Wisniewski S, Zisook S, Fava M, Sung S, Haley C . Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D report. Psychol Med. 2011; 42(6):1131-49. DOI: 10.1017/S0033291711002170. View

13.

Herzog D, Wagner S, Ruckes C, Tadic A, Roll S, Harter M . Guideline adherence of antidepressant treatment in outpatients with major depressive disorder: a naturalistic study. Eur Arch Psychiatry Clin Neurosci. 2017; 267(8):711-721. DOI: 10.1007/s00406-017-0798-6. View

14.

Fife D, Feng Y, Wang M, Chang C, Liu C, Juang H . Epidemiology of pharmaceutically treated depression and treatment resistant depression in Taiwan. Psychiatry Res. 2017; 252:277-283. DOI: 10.1016/j.psychres.2017.03.006. View

15.

Nunez N, Joseph B, Pahwa M, Kumar R, Resendez M, Prokop L . Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis. J Affect Disord. 2022; 302:385-400. PMC: 9328668. DOI: 10.1016/j.jad.2021.12.134. View

16.

Vigo D, Haro J, Hwang I, Aguilar-Gaxiola S, Alonso J, Borges G . Toward measuring effective treatment coverage: critical bottlenecks in quality- and user-adjusted coverage for major depressive disorder. Psychol Med. 2020; :1-11. PMC: 9341444. DOI: 10.1017/S0033291720003797. View

17.

Gaynes B, Lux L, Gartlehner G, Asher G, Forman-Hoffman V, Green J . Defining treatment-resistant depression. Depress Anxiety. 2019; 37(2):134-145. DOI: 10.1002/da.22968. View

18.

Posner K, Brown G, Stanley B, Brent D, Yershova K, Oquendo M . The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011; 168(12):1266-77. PMC: 3893686. DOI: 10.1176/appi.ajp.2011.10111704. View

19.

Kennedy S, Lam R, McIntyre R, Tourjman S, Bhat V, Blier P . Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. Can J Psychiatry. 2016; 61(9):540-60. PMC: 4994790. DOI: 10.1177/0706743716659417. View

20.

De Carlo V, Calati R, Serretti A . Socio-demographic and clinical predictors of non-response/non-remission in treatment resistant depressed patients: A systematic review. Psychiatry Res. 2016; 240:421-430. DOI: 10.1016/j.psychres.2016.04.034. View